Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CAPS Rating: 3 out of 5

The Company is a biopharmaceutical company that discovers, develops, and intends to commercialize pharmaceutical products for the treatment of serious medical conditions.

Results 1 - 20 of 41 : 1 2 3 Next »

Recs

0
Member Avatar wmsk (< 20) Submitted: 11/15/2014 7:57:08 AM : Outperform Start Price: $396.03 REGN Score: +2.12

Its blockbuster drug Eylea, currently used by Ophthalmologists, is increasing. Other drugs in the pipeline will only enhance the stock value.

Recs

0
Member Avatar Parka (< 20) Submitted: 11/7/2014 9:13:10 AM : Outperform Start Price: $375.10 REGN Score: +7.45

Yes

Recs

0
Member Avatar davidm9999 (< 20) Submitted: 10/19/2014 8:52:59 PM : Underperform Start Price: $367.79 REGN Score: -1.59

As I have outlined 10 times or so to zero feedback and onlooker commentary - REGN is at or near its peak - Roth Capital aka chop shop wants this stock to go to $410 - most optimistic technicians call it $380 - currently $370 in other words, it will be facing a literal mountain of negative pressure in order to move any higher and if it does, it still will not move very far. Point being, and I've made the mistake of shorting this stock on the way up, get shot this stock - preferably outright shorting, but puts will work to, assuming they are appropriately spaced out over the next 24 months

Recs

1
Member Avatar Morass (55.86) Submitted: 9/6/2014 9:08:50 PM : Outperform Start Price: $349.43 REGN Score: +14.49

REGN has a pipeline of potential biotech products.

Recs

0
Member Avatar trackjakeambrose (56.72) Submitted: 7/20/2014 10:06:15 PM : Outperform Start Price: $306.20 REGN Score: +29.10

1 ;-)

Recs

0
Member Avatar SqwiiTrader (< 20) Submitted: 5/7/2014 6:06:24 PM : Underperform Start Price: $310.40 REGN Score: -28.20

Biotech bull market top

Recs

0
Member Avatar Jbshow (< 20) Submitted: 4/29/2014 6:18:44 PM : Outperform Start Price: $278.42 REGN Score: +37.39

Regeneron has some leading drugs that will get a boost from the aging baby generation.

Recs

1
Member Avatar TMFTycoon (47.43) Submitted: 3/20/2014 3:53:53 PM : Outperform Start Price: $328.69 REGN Score: +14.67

Things are looking good for Eylea, one of Regeneron's drugs, and it is scheduled for further regulatory decisions and Phase III testing later this year.

Recs

0
Member Avatar Chemdawg (25.95) Submitted: 3/7/2014 2:07:49 AM : Outperform Start Price: $341.83 REGN Score: +10.52

12 shots in the eye per year Vs 52 shots in the eye for the competition ....which would you choose?

Recs

0
Member Avatar d3ming (< 20) Submitted: 1/31/2014 1:30:34 PM : Outperform Start Price: $291.02 REGN Score: +25.08

zzporte

Recs

0
Member Avatar stocklade (40.84) Submitted: 1/17/2014 1:28:35 AM : Outperform Start Price: $290.92 REGN Score: +28.73

Macular increasing as population ages.

Recs

0
Member Avatar ForgetGold (< 20) Submitted: 1/15/2014 6:44:27 PM : Outperform Start Price: $287.72 REGN Score: +30.41

Research and development. Cutting edge products

Recs

0
Member Avatar dschmedeke (< 20) Submitted: 12/7/2013 12:13:39 AM : Outperform Start Price: $284.52 REGN Score: +30.28

Regn has many unique products in the pipeline including Elyla and has partnered with Bayer in Europe.

Recs

0
Member Avatar 1russianguy (82.53) Submitted: 10/9/2013 2:10:38 PM : Outperform Start Price: $278.17 REGN Score: +22.82

Liked by Hilary Kramer. Coming with replacement of lipitor, which 70% of doctors will be subscribing. Buy long-term on pull back.
http://www.bloomberg.com/video/hilary-kramer-s-healthcare-play-RWxPwyIHT_CPhQrCnHr_1w.html

Recs

1
Member Avatar paek813 (99.67) Submitted: 9/26/2013 5:08:39 PM : Outperform Start Price: $228.92 REGN Score: +54.09

s&p 4 star:

August 19, 2013

S&P RAISES OPINION ON SHARES OF REGENERON PHARMA TO BUY FROM HOLD ON VALUATION (REGN 229.56 ****):

We keep our forward P/E-based target price at $284, but now view REGN's valuation as attractive following a 15% decline since reporting Q2 earnings earlier this month. We attribute the share price weakness to signs of moderating sales growth of Eylea for eye disease wet AMD. While we expect long-term competition for the franchise, we see its approval for diabetes macular edema, likely by '15, providing a long-term growth driver. We also anticipate robust news flow from its clinical pipeline over the coming months, led by Phase III candidate Alirocumab for high cholesterol.
/S.Silver

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

August 29, 2013

REGN announces Eylea (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO).

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

Today:

RBC says increased likelihood of a bill increasing FDA's power to regulate compounding pharmacies, especially those who produce large volumes of compounded drug and ship them across state lines, increases the likelihood of a shift away from Avastin to REGN's Eylea. Maintains outperform.

Recs

0
Member Avatar 1picks (88.00) Submitted: 9/24/2013 10:08:03 AM : Outperform Start Price: $294.69 REGN Score: +17.19

Liked by Hilary Kramer. Coming with replacement of lipitor, which 70% of doctors will be subscribing. Buy long-term on pull back.
http://www.bloomberg.com/video/hilary-kramer-s-healthcare-play-RWxPwyIHT_CPhQrCnHr_1w.html

Recs

0
Member Avatar Elmer22003 (48.61) Submitted: 9/18/2013 10:51:17 PM : Outperform Start Price: $309.91 REGN Score: +13.20

MONSTER. Yes, REGN has done nothing but go through the roof but there is still HUGE potential here. Unbelievable pipeline. REGN will is overweight and will be in 400's before 2015.

Recs

0
Member Avatar pramathmalik (57.54) Submitted: 7/2/2013 4:03:02 AM : Outperform Start Price: $230.14 REGN Score: +50.00

Cramer

Recs

1
Member Avatar ChipNPutt11 (83.08) Submitted: 4/29/2013 3:58:12 PM : Outperform Start Price: $215.48 REGN Score: +60.69

Very well run, finally a marketable product in Eylea. Great pipeline. I've owned since 1997, mainly because Dr. Roy Vagelos got invovled after retiring from Merck. He attracted a lot of early funding. They comapny is expanding their R&D and headquaters facility in Tarrytown and adding 400 to staff. Plenty of funding deals available for them now.

Recs

1
Member Avatar TMFTiptree (26.52) Submitted: 4/27/2013 8:47:26 PM : Outperform Start Price: $216.25 REGN Score: +60.26

Killer pipeline, great management.

Results 1 - 20 of 41 : 1 2 3 Next »

Featured Broker Partners


Advertisement